JP2021519271A5 - - Google Patents

Info

Publication number
JP2021519271A5
JP2021519271A5 JP2020551349A JP2020551349A JP2021519271A5 JP 2021519271 A5 JP2021519271 A5 JP 2021519271A5 JP 2020551349 A JP2020551349 A JP 2020551349A JP 2020551349 A JP2020551349 A JP 2020551349A JP 2021519271 A5 JP2021519271 A5 JP 2021519271A5
Authority
JP
Japan
Prior art keywords
disorder
agonists
compound
free
formula
Prior art date
Application number
JP2020551349A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183546A5 (https=
JP2021519271A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023687 external-priority patent/WO2019183546A1/en
Publication of JP2021519271A publication Critical patent/JP2021519271A/ja
Publication of JPWO2019183546A5 publication Critical patent/JPWO2019183546A5/ja
Publication of JP2021519271A5 publication Critical patent/JP2021519271A5/ja
Priority to JP2024102491A priority Critical patent/JP2024123211A/ja
Pending legal-status Critical Current

Links

JP2020551349A 2018-03-23 2019-03-22 有機化合物 Pending JP2021519271A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102491A JP2024123211A (ja) 2018-03-23 2024-06-26 有機化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647482P 2018-03-23 2018-03-23
US62/647,482 2018-03-23
PCT/US2019/023687 WO2019183546A1 (en) 2018-03-23 2019-03-22 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102491A Division JP2024123211A (ja) 2018-03-23 2024-06-26 有機化合物

Publications (3)

Publication Number Publication Date
JP2021519271A JP2021519271A (ja) 2021-08-10
JPWO2019183546A5 JPWO2019183546A5 (https=) 2022-02-17
JP2021519271A5 true JP2021519271A5 (https=) 2022-02-17

Family

ID=67987581

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551349A Pending JP2021519271A (ja) 2018-03-23 2019-03-22 有機化合物
JP2024102491A Pending JP2024123211A (ja) 2018-03-23 2024-06-26 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102491A Pending JP2024123211A (ja) 2018-03-23 2024-06-26 有機化合物

Country Status (12)

Country Link
US (1) US20210008065A1 (https=)
EP (1) EP3768271B1 (https=)
JP (2) JP2021519271A (https=)
CN (1) CN112088004A (https=)
AU (2) AU2019236860B2 (https=)
BR (1) BR112020019181A2 (https=)
CA (1) CA3095101A1 (https=)
DK (1) DK3768271T3 (https=)
FI (1) FI3768271T3 (https=)
IL (2) IL303857B2 (https=)
MX (1) MX2020009929A (https=)
WO (1) WO2019183546A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305990B2 (en) * 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
CN108883111B (zh) 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
IL283963B2 (en) 2018-12-17 2025-01-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
JP7533361B2 (ja) * 2021-05-26 2024-08-14 株式会社三洋物産 遊技機
JP2025521115A (ja) 2022-05-18 2025-07-08 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4665344A1 (en) 2023-02-17 2025-12-24 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods
WO2025257090A1 (en) 2024-06-10 2025-12-18 Interquim, S.A. Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
MXPA01012969A (es) 1999-06-15 2003-10-14 Bristol Myers Squibb Pharma Co Gamma-carbolinas fusionadas de heterociclo sustituido.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (ko) 2002-07-29 2007-03-26 알자 코포레이션 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 置換ヘテロ環縮合ガンマ−カルボリン類固体
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
SG11201501894VA (en) * 2012-09-14 2015-04-29 Abbvie Inc Tricyclic quinoline and quinoxaline derivatives
MX365969B (es) * 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
RU2016143091A (ru) * 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego

Similar Documents

Publication Publication Date Title
JP2021519271A5 (https=)
RU2020123764A (ru) Органические соединения
RU2016143091A (ru) Органические соединения
RU2018137496A (ru) Органические соединения
JP2017509686A5 (https=)
JPWO2019183546A5 (https=)
FI3768271T3 (fi) Orgaanisia yhdisteitä
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
JP2011523949A5 (https=)
JP2006143749A5 (https=)
JP7245509B2 (ja) 吃音を治療するための融合ベンズアゼピン
JP2015516395A5 (https=)
BRPI0608475A2 (pt) derivados de diidrobenzofurano e usos dos mesmos
JP2016539144A5 (https=)
RU2007139541A (ru) Производные хромана и хромена и их применение
MX2008012094A (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion.
JP2015535290A (ja) 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法
RU2019143572A (ru) Композиции для лечения посттравматического стрессового расстройства
CN101198322A (zh) 用于治疗或预防抑郁症的新治疗组合
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP2022051745A5 (https=)
MX2009007405A (es) Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.
JP2007505156A5 (https=)
RU2020118505A (ru) Комбинация модуляторов nmda-рецептора (рапастинеля) для применения в комбинированной терапии (расстройства сна и цнс)
CN101163477A (zh) 多介质多巴胺转运抑制剂,以及其相关应用